Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE

por Panaccione, R, Colombel, J-F, Sandborn, W J, D'Haens, G, Zhou, Q, Pollack, P F, Thakkar, R B, Robinson, A M
Publicado 2013

Randomised clinical study: discrepancies between patient‐reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis

por Jharap, B., Sandborn, W. J., Reinisch, W., D'Haens, G., Robinson, A. M., Wang, W., Huang, B., Lazar, A., Thakkar, R. B., Colombel, J.‐F.
Publicado 2015

Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventiona...

por Colombel, J.‐F., Jharap, B., Sandborn, W. J., Feagan, B., Peyrin‐Biroulet, L., Eichner, S. F., Robinson, A. M., Mostafa, N. M., Zhou, Q., Thakkar, R. B.
Publicado 2016